Regional hyperthermic perfusion with melphalan after surgery for recurrent malignant melanoma of the extremities – Long-term follow-up of a randomised trial

2014 ◽  
Vol 30 (5) ◽  
pp. 295-298 ◽  
Author(s):  
Roger Olofsson Bagge ◽  
Jan Mattsson ◽  
Lo Hafström
Keyword(s):  
Malignant Melanoma ◽  
Randomised Trial ◽  
Long Term Follow Up

A randomized trial of levamisole versus placebo as adjuvant therapy in malignant melanoma.

1991 ◽  
Vol 9 (5) ◽  
pp. 736-740 ◽  
Author(s):  
L E Spitler
Keyword(s):  
Malignant Melanoma ◽  
Adjuvant Therapy ◽  
Randomized Trial ◽  
Control Groups ◽  
Disease Free Interval ◽  
Significant Difference ◽  
Long Term Follow Up ◽  
And Control

We conducted a long-term follow-up (median, 10.5 years) of patients included in a randomized trial of levamisole versus placebo as surgical adjuvant therapy in 203 patients with malignant melanoma. Of the patients randomized, 104 received levamisole, and 99 received placebo. The results show that there is no difference between the treatment and control groups with regard to any of the three end points analyzed. These included disease-free interval, time to appearance of visceral metastasis, and survival. Moreover, there was no significant difference between the treatment and control groups after adjusting for age, sex, or stage of disease.

scholarly journals Expression of HGF, pMet, and pAkt is related to benefit of radiotherapy after breast‐conserving surgery: a long‐term follow‐up of the SweBCG91‐RT randomised trial

2020 ◽  
Vol 14 (11) ◽  
pp. 2713-2726
Author(s):  
Martin Sjöström ◽  
Cynthia Veenstra ◽  
Erik Holmberg ◽  
Per Karlsson ◽  
Fredrika Killander ◽  
...  
Keyword(s):  
Randomised Trial ◽  
Breast Conserving Surgery ◽  
Long Term Follow Up

scholarly journals Wide versus narrow excision margins for high-risk, primary cutaneous melanomas: long-term follow-up of survival in a randomised trial

2016 ◽  
Vol 17 (2) ◽  
pp. 184-192 ◽  
Author(s):  
Andrew J Hayes ◽  
Lauren Maynard ◽  
Gillian Coombes ◽  
Julia Newton-Bishop ◽  
Michael Timmons ◽  
...  
Keyword(s):  
High Risk ◽  
Randomised Trial ◽  
Long Term Follow Up ◽  
Excision Margins

scholarly journals A Case of Late Delayed Metastasis of Malignant Melanoma After 27 Years After First Excision

2020 ◽  
Vol 2 (2) ◽  
pp. 1-2
Author(s):  
Claudio Bravin ◽  
◽  
Carlo Braga ◽  
Gaetana Rizzi ◽  
◽  
...  
Keyword(s):  
Malignant Melanoma ◽  
Histological Examination ◽  
Mitotic Rate ◽  
Skin Tumor ◽  
Melanocytic Lesions ◽  
Long Term Follow Up ◽  
Neoplastic Process ◽  
Abdominal Lesion

We report a case of an ultra-late delayed metastasis of malignant melanoma 27 years after the excision of the first tumor. The patient is a 67 years old Italian woman. She underwent a primary excision of a skin lesion of 1cm in diameter on the lower third of the left leg in 1984 when she was 39. According to the histological examination the lesion was a lentigo malign melanoma with an epithelial histological pattern with intra- and subepidermal diffusion. The lesion was 2.2 mm in thickness (Breslow) and was a Clark level IV melanoma; mitotic rate was 6 mitosis/mm2. No melanocytic lesions were found on excision edges and no lymph nodes were removed and examined. In March 2011, when the woman was 67 years old, an inguinal lymph node and an intraabdominal lesion were considered suspect for neoplastic process during a clinical exam of the GP. A histological examination and an eco-imaging procedure described the lesions as metastasis of malignant melanoma probably related to the first skin tumor. Within a few days she was treated with the excision of the abdominal lesion, the total greater omentectomy and the lymphadenectomy of the left inguinal region. Histological examination confirmed the suspect of metastasis of the first melanoma with a predominant epithelioid growing pattern. This case underlines the need of a long-term follow-up period for patients with melanoma.

Comparison of two standard chemotherapy regimens for good-prognosis germ-cell tumors: Updated analysis of a randomized trial with 8 years follow-up

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5016-5016
Author(s):  
P. S. Grimison ◽  
M. R. Stockler ◽  
D. B. Thomson ◽  
I. N. Olver ◽  
V. J. Harvey ◽  
...  
Keyword(s):  
Overall Survival ◽  
Germ Cell ◽  
Survival Benefit ◽  
Randomised Trial ◽  
Good Prognosis ◽  
Hazard Ratio ◽  
Standard Chemotherapy ◽  
Long Term Follow Up

5016 Background: We performed a multicentre randomised trial for good-prognosis germ-cell tumours of two standard chemotherapy regimens containing bleomycin (B), etoposide (E) and cisplatin (P). Accrual was stopped early, after interim analysis with a median follow-up of 33 months found a survival benefit for the regimen similar to Indiana University BEP, compared with the less dose-intense regimen (Toner, Lancet 2001). Here we report on long-term outcomes and patterns of relapse. Methods: Patients with a good prognosis defined by modified Memorial Sloan-Kettering criteria were randomised to 3B90E500P (3 cycles every 21 days of B 30 kU on days 1, 8 and 15, E 100 mg/m2 on days 1–5, and P 20 mg/m2 on days 1–5); or 4B30E360P (4 cycles every 21 days of B 30 kU on day 1, E 120 mg/m2 on days 1–3, and P 100 mg/m2 on day 1). Overall survival was the primary endpoint. Progression-free survival (PFS) was a secondary endpoint. All analyses were by intention-to-treat and with 2-sided p-values. Results: 166 patients were randomised, 83 to each regimen. Median follow-up is now 8.5 years and all but 5 have been followed ≥ 5 years. Overall survival remains substantially better with 3B90E500P than 4B30E360P (8YS 92% vs 83%, hazard ratio 0.38, 95% CI 0.15 to 0.97, p=0.037), and remains significant when analyses were restricted to 138 patients with good prognosis by IGCCCG criteria (p=0.035). Trends for PFS favour 3B90E500P but are not statistically significant (8YPFS 86% vs 79%, hazard ratio 0.6, 95% CI 0.3 to 1.1, p=0.15). 7 of 15 relapses occurring within 2 years after randomisation were fatal, but all 4 relapses occurring > 2 years after randomisation were fatal. Conclusions: The survival benefit of 3B90E500P compared to 4B30E360P was maintained with long-term follow-up. The occurrence of relapses beyond 2 years affirms the importance of long-term follow-up. Late relapses in this study were associated with uniformly poor outcomes. [Table: see text] No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document